Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease

Mathai, Stephen C., Hummers, Laura K., Champion, Hunter C., Wigley, Fredrick M., Zaiman, Ari, Hassoun, Paul M., Girgis, Reda E.·2009·Arthritis & Rheumatism

Abstract

Objective: Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulmonary arterial hypertension [PAH]) or associated with interstitial lung disease (ILD). This study was undertaken to characterize determinants of survival among SSc patients with either type of PH who received PAH‐specific therapy. Methods: Consecutive SSc patients with PAH or ILD‐associated PH confirmed by right heart catheterization were included in the study. Kaplan‐Meier and Cox proportional hazards models were used to compare survival between SSc patients with PAH and those with ILD‐associated PH and to identify predictors of survival. Results: Fifty‐nine patients (39 with PAH and 20 with ILD‐associated PH) were identified. The majority (15 of 20 with ILD‐associated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy. Median followup time was 4.4 years (range 2.7–7.4 years). Survival was significantly worse in SSc patients with ILD‐associated PH than in those with PAH (1‐, 2‐, and 3‐year survival rates 82%, 46%, and 39% versus 87%, 79%, and 64%, respectively; P < 0.01 by log rank test). In a multivariable analysis, ILD‐associated PH was associated with a 5‐fold increase in risk of death compared with PAH. Pulmonary vascular resistance index was also an independent predictor of mortality in the overall cohort (hazard ratio 1.05, P < 0.01) and was a significant univariable risk factor in each group separately. Type of initial PAH therapy and the use of warfarin were not related to survival. Conclusion: Survival in SSc complicated by PH remains poor despite currently available treatment options. While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD‐associated PH is particularly grim. Early diagnosis and treatment may improve outcomes since worsening hemodynamic factors were associated with reduced survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.24267

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 265

Metadata

Authors
Mathai, S. C., Hummers, L. K., Champion, H. C., Wigley, F. M., Zaiman, A., Hassoun, P. M., & Girgis, R. E.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2009-01-29
Volume
60
Issue
2
Pages
569-577
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2003012980
Cited by
265
References
45
FWCI
18.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. https://app.cochat.ai/papers/10.1002/art.24267
The paper
Mathai, S. C., Hummers, L. K., Champion, H. C., Wigley, F. M., Zaiman, A., Hassoun, P. M., & Girgis, R. E. (2009). Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis & Rheumatism. https://doi.org/10.1002/art.24267

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.